UBC researchers awarded more than $6.5 million from Brain Canada to advance neuroscience research
VANCOUVER, BC, June 13, 2025 /CNW/ - UBC Faculty of Medicine researchers have been awarded more than $6.5 million from Brain Canada's Platform Support Grants program to support two pioneering neuroscience research platforms. The funding will help accelerate discovery and foster open science, positioning Canada at the forefront of global brain and spine health innovation.
The two newly funded platforms are:
International Spinal Cord Injury Biobank (ISCIB): Promoting Global Spinal Cord Injury Research Through Human Biobanking, led by Dr. Brian Kwon, which will expand access to vital human biological samples for spinal cord injury research, enabling researchers worldwide to advance treatments and improve outcomes for patients.Total Grant Awarded: $1,866,750
The University of British Columbia Genes, Cells and Circuits (UBC-GC2) Platform for Next-Generation Multiscale Brain Research, led by Dr. Mark Cembrowski, which will integrate state-of-the-art technologies to map brain function and connectivity from molecules to entire circuits, unlocking insights into complex brain disorders.Total Grant Awarded: $4,845,000
"This platform represents a critical step toward advancing spinal cord injury research globally," said Dr. Brian Kwon, a Professor in the Department of Orthopaedics and the Director of ICORD. "By providing access to high-quality human biosamples, we're enabling researchers worldwide to develop and test new treatments that could dramatically improve quality of life for patients."
"With the UBC-GC2 platform, we're bridging the gap between molecular biology and systems neuroscience," said Dr. Mark Cembrowski, an Associate Professor in the Department of Cellular and Physiological Sciences. "By integrating cutting-edge technologies, we'll be able to study brain function at an unprecedented scale and resolution. This will not only advance our understanding of brain disorders but also open new avenues for treatments."
These platforms exemplify UBC's commitment to advancing neuroscience and fostering collaboration within and beyond Canada's borders.
"The UBC neuroscience community is grateful for Brain Canada's continued support," said Dr. Lynn Raymond, Co-Director of the Djavad Mowafaghian Centre for Brain Health at UBC. "These investments will strengthen our capacity to deliver world-class research and transform brain health for people across the lifespan."
Viviane Poupon, President and CEO of Brain Canada, emphasized the importance of these initiatives: "By supporting these cutting-edge platforms, Brain Canada is building the infrastructure that will accelerate brain and spinal cord research and foster open science collaboration. We're proud to partner with UBC to drive innovations that will impact millions of lives."
These two platforms are part of Brain Canada's broader Platform Support Grants (PSG) initiative, which has already invested in numerous projects across Canada to empower researchers with shared tools, data resources, and collaborative opportunities. The full list of funded platforms will be unveiled later this month.
Brain Canada is contributing over $18 million in this year's PSG program through the Canada Brain Research Fund (CBRF), funded by Health Canada, as well as matching donations from sponsors for a total investment of $36.8 million. By enabling access to cutting-edge tools and specialized skills beyond the reach of individual researchers, the PSG program plays a vital role in strengthening the research landscape.
"Research and innovation are essential to unlocking new treatments, improving recovery, and enhancing quality of life for people affected by brain health issues and injuries," said the Honourable Marjorie Michel, Minister of Health. "Through the Canada Brain Research Fund, the Government of Canada is very pleased to support these new neuroscience research platforms, which bring together experts from different fields, integrate cutting-edge technologies and focus on improving patient outcomes."
SOURCE Brain Canada
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2025/13/c6573.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 hours ago
- Yahoo
Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference
HERZLIYA, Israel and CALGARY, AB, June 20, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces that the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: has been officially accepted for presentation at PAINWEEK 2025, the national conference on pain management, taking place this September in Las Vegas, Nevada. PAINWEEK is a prestigious event that brings together leading clinicians, researchers, and educators in the field of pain medicine, offering a unique platform to showcase innovative research and best practices. The narrative review, selected through a competitive peer-review process, provides important insights into the potential of synthetic cannabidiol (CBD), administered through extended-release formulations, as a well-tolerated, non-opioid analgesic alternative. Innocan is developing LPT-CBD, an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by multiple animal studies, LPT-CBD has demonstrated steady plasma CBD levels for up to four weeks, prolonged pain relief, and excellent tolerability—offering a promising alternative to current opioid medications and addressing the urgent need to reduce opioid dependency. LPT-CBD will be showcased at the PAINWEEK conference to thousands of healthcare professionals and potential pharmaceutical partners, positioning it at the forefront of groundbreaking non-opioid chronic pain management solutions. "We are honored to be included among the esteemed voices presenting at PAINWEEK this year," said Iris Bincovich, Chief Executive Officer of Innocan. "This recognition underscores our commitment to advancing evidence-based pain care and contributing meaningful research to the field." About Innocan: Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales. Contact Information: For Innocan Pharma Corporation:Iris Bincovich, CEO+1 5162104025+972-54-3012842+442037699377info@ NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law. Logo: View original content: SOURCE Innocan Pharma Corporation View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Major Investment to Transform Mental Health Research
OTTAWA, ON, June 19, 2025 /CNW/ - Brain Canada is proud to announce its support for the development of the Brain Imaging Centre Advanced Multi-modal neuroimaging Platform for Psychiatry (BIC-AMPP) at The Royal Ottawa Health Care Group's BIC. Through its 2024 Platform Support Grants (PSG) program, Brain Canada is partnering with The Royal to invest $1.9 million in this groundbreaking initiative, which will integrate multiple brain imaging modalities to revolutionize mental health research. Led by Dr. Georg Northoff of the University of Ottawa's Institute of Mental Health Research (IMHR), the BIC-AMPP project brings together experts in MRI, PET, and EEG imaging to unlock the complex biochemical, structural, and functional changes associated with mental illness. This rare and technically advanced platform will allow researchers to simultaneously capture a more thorough and integrated picture of the brain, laying the groundwork for improved diagnostics and personalized treatments. "This investment represents a step-change in the capabilities of our team and our infrastructure, positioning Canada at the forefront of brain imaging research for mental health," said Dr. Florence Dzierszinski, President and CEO of the IMHR and vice-president of research at The Royal. "Simultaneous tri-modal imaging is only being actively pursued in two other centres in the world, yet offers endless possibilities with the right technology and skills." "This platform will enable us to link brain structure, chemistry, and function in real time," said Katie Dinelle, Administrative Director of The Royal's Clinical Brain Research Centre. "It will give us a more complete picture of mental illness and open new doors for discovery." "Mental health research has long been limited by our inability to fully understand how the brain's structure, chemistry, and function interact," said Dr. Georg Northoff, lead Principal Investigator for the BIC-AMPP. "By integrating multiple imaging modalities in a single platform, we can finally start to connect the dots. This will help us move beyond fragmented insights toward a more holistic understanding of mental illness—one that can inform better, more personalized treatments." The BIC-AMPP platform is designed to foster collaboration among scientists and provide unprecedented access to simultaneous multi-modal imaging, positioning The Royal as a hub for innovation and knowledge mobilization. Supported by expert scientific staff and a secure, open-access data-sharing infrastructure, the platform will accelerate discoveries that improve mental health care in Canada and beyond. Dr. Viviane Poupon, President and CEO of Brain Canada, emphasized the importance of this initiative: "The BIC-AMPP represents a major leap forward in our ability to understand mental illness and develop personalized treatments. Brain Canada is proud to support this visionary platform, which underlines Canada's position as a global leader in brain imaging research." Brain Canada is contributing over $18 million in this year's PSG program through the Canada Brain Research Fund (CBRF), funded by Health Canada, as well as matching donations from sponsors for a total investment of $36.8 million. By enabling access to cutting-edge tools and specialized skills beyond the reach of individual researchers, the PSG program plays a vital role in strengthening the research landscape. "Research and innovation deepen our understanding, unlock new treatments, and improve quality of life for people affected by mental illness," said the Honourable Marjorie Michel, Minister of Health. "Through the Canada Brain Research Fund, the Government of Canada is pleased to support this initiative, bringing together experts from different fields to accelerate discoveries that will improve mental health care for Canadians." Over the coming weeks, Brain Canada will unveil the full list of 14 research platforms selected to receive PSG funding. The total investment of $36.8 million represents a major step forward in Canada's ability to support cutting-edge brain research and improve outcomes for people living with brain-disorders. For more information, please visit The Royal is one of Canada's foremost mental health care, teaching, and research hospitals and is home to the Royal Ottawa Mental Health Centre, the Brockville Mental Health Centre, the University of Ottawa Institute of Mental Health and the Royal Ottawa Foundation for Mental Health. Our mission is to transform the lives of people living with complex mental illness and addictions. Learn more about The Royal, our services, and our impact. SOURCE Brain Canada View original content to download multimedia:
Yahoo
2 days ago
- Yahoo
Real forward Mbappe in hospital
Kylian Mbappe was involved in Real Madrid training earlier this week in Palm Beach, Florida [Getty Images] Real Madrid forward Kylian Mbappe is in hospital with gastroenteritis after missing their Club World Cup opener against Al-Hilal. The France captain, 26, missed training on Tuesday with a fever and did not play in Wednesday's 1-1 draw against the Saudi Arabian side. Advertisement A Real statement on Thursday said Mbappe has "an acute case of gastroenteritis" and was admitted to hospital for "a series of tests". Gastroenteritis is an infection in the gut which can cause vomiting and diarrhoea. Real's next game is against Pachuca on Sunday at 20:00 BST. There is no indication whether Mbappe could be available for the game. Mbappe scored 43 goals in 56 games in all competitions for Real in his first season after joining on a free transfer from Paris St-Germain. This is Real's first competition under Xabi Alonso, who replaced Carlo Ancelotti as manager at the end of the La Liga season. Real won the Uefa Super Cup and Fifa Intercontinental Cup in Mbappe's first season in Spanish football.
